Status:
COMPLETED
Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University
Collaborating Sponsors:
Pfizer
Conditions:
Cancer
Head and Neck Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study is using the combination of radiation and antiangiogenic agents (agents that destroy existing blood vessels) seems to be an approach to tumor cure.
Detailed Description
The combination of ionizing radiation and antiangiogenic agents seems to be a counterintuitive approach to tumor cure because oxygen is a potent radiosensitizer and a reduction in oxygen concentration...
Eligibility Criteria
Inclusion
- Minimum 2 week course of radiation therapy
- Solid tumors of the central nervous system, head and neck, thorax, and pelvis
Exclusion
- Major surgery or radiation therapy within 4 weeks starting study treatment
- Grade 3 hemorrhage within 4 weeks
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT00437372
Start Date
March 1 2007
End Date
December 1 2010
Last Update
May 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107